Novo Nordisk A/S (NVO)vsSeaboard Corporation (SEB)
NVO
Novo Nordisk A/S
$46.07
+0.59%
HEALTHCARE · Cap: $202.85B
SEB
Seaboard Corporation
$4,540.14
+0.29%
INDUSTRIALS · Cap: $4.34B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 3235% more annual revenue ($327.80B vs $9.83B). NVO leads profitability with a 37.2% profit margin vs 5.9%. SEB appears more attractively valued with a PEG of 0.65. NVO earns a higher WallStSmart Score of 74/100 (B).
NVO
Strong Buy74
out of 100
Grade: B
SEB
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NVO.
Margin of Safety
+49.9%
Fair Value
$11112.70
Current Price
$4540.14
$6572.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Attractively priced relative to earnings
Every $100 of equity generates 71 in profit
Keeps 37 of every $100 in revenue as profit
Strong operational efficiency at 61.6%
Earnings expanding 67.1% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Earnings expanding 277.0% YoY
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
3.6% revenue growth
5.9% margin — thin
Operating margin of 4.0%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVO
The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.
Bull Case : SEB
The strongest argument for SEB centers on P/E Ratio, Price/Book, EPS Growth. PEG of 0.65 suggests the stock is reasonably priced for its growth.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio.
Bear Case : SEB
The primary concerns for SEB are Revenue Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
NVO profiles as a growth stock while SEB is a value play — different risk/reward profiles.
NVO carries more volatility with a beta of 0.35 — expect wider price swings.
NVO is growing revenue faster at 24.0% — sustainability is the question.
NVO generates stronger free cash flow (12.0B), providing more financial flexibility.
Bottom Line
NVO scores higher overall (74/100 vs 65/100), backed by strong 37.2% margins and 24.0% revenue growth. SEB offers better value entry with a 49.9% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Seaboard Corporation
INDUSTRIALS · CONGLOMERATES · USA
Seaboard Corporation is a global agribusiness and transportation company. The company is headquartered in Merriam, Kansas.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?